Lymphoid enhancer-binding factor 1 mRNA 3' untranslated region (LEF1 mRNA 3' UTR) (LEF1 mRNA 3' UTR)

The Lymphoid enhancer-binding factor 1 (LEF1) mRNA 3' untranslated region (UTR) is a critical regulatory segment of the LEF1 transcript that governs the stability and translation of the LEF1 protein (Source: PubMed PMID: 21822215). LEF1 is a key transcription factor within the canonical Wnt/beta-catenin signaling pathway, playing a vital role in cell proliferation, differentiation, and lineage commitment (Source: UniProt P17535). The 3' UTR contains multiple conserved binding sites for microRNAs (miRNAs), such as miR-26a and miR-34a, which act as post-transcriptional rheostats to modulate LEF1 expression levels (Source: PubMed PMID: 25605123). Dysregulation of this region, often leading to the pathological overexpression of LEF1, is a hallmark of several malignancies, most notably chronic lymphocytic leukemia (CLL) and various solid tumors (Source: PubMed PMID: 19095757). Therapeutic strategies targeting the LEF1 mRNA 3' UTR involve the use of miRNA mimics or antisense oligonucleotides (ASOs) designed to induce mRNA degradation or block translation, thereby inhibiting the oncogenic Wnt signaling cascade (Source: PubMed PMID: 28438197).

Other names

LEF1 3' UTRLymphoid enhancer-binding factor 1 3' UTRLEF-1 3'-untranslated regionLEF1 3'-UTR

Targeted degradation of LEF1 mRNA or inhibition of translation through microRNA-mediated silencing or antisense-induced RNA interference.